Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution
Sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is a sterile topical ophthalmic solution combining an antibacterial and a corticosteroid. Each mL Contains: Actives: sulfacetamide sodium (as the monohydrate) 100 mg, prednisolone sodium phosphate 2.5 mg (equivalent to prednisolone phosphate 2.3 mg). Preservative: thimerosal 0.1 mg. Inactives: edetate disodium, poloxamer 407, boric acid, sodium hydroxide and/or hydrochloric acid (to adjust pH) and water for injection. pH range is 6.5 to 7.5.
Sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies.
The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species.
The product does not provide adequate coverage against: Neisseria species, Pseudomonas species, Serratia marcescens.
A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs.
Clinical Trials Related to Sulfacetamide and Prednisolone (Sulfacetamide / Prednisolone Ophthalmic)
Effects of Brain Stimulation on Learning and Reasoning [Completed]
Imaging studies of the brain have revealed the different areas involved in the processes of
learning and reasoning. However, the specific role these regions play in these processes, or
if stimulating these areas can improve these processes is unknown.
Researchers would like to use repetitive transcranial stimulation (rTMS) to better understand
the roles of individual brain regions on the processes of learning and reasoning. Repetitive
transcranial magnetic stimulation (rTMS) involves the placement of a cooled electromagnet
with a figure-eight coil on the patient's scalp, and rapidly turning on and off the magnetic
flux. This permits non-invasive, relatively localized stimulation of the surface of the
brain (cerebral cortex). The effect of magnetic stimulation varies, depending upon the
location, intensity and frequency of the magnetic pulses.
The purpose of this study is to use rTMS to help determine the roles of different brain
regions in the development of implicit learning of motor sequences and analogic reasoning.
In addition, researchers hope to evaluate if stimulation of these regions speeds up the
process of learning or analogic reasoning.
SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture. [Recruiting]
The purpose of this study is to evaluate the efficacy and safety of risedronate sodium
(Actonel®) after a wrist fracture in postmenopausal women.
Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru [Completed]
In Peru, Mefloquine plus Artesunate (MAS3), is the current first line treatment for P.
falciparum malaria in the Amazonian Region, and has proved its efficacy against
multi-resistant P. falciparum parasites, but several side effects have been reported.
Dihydroartemisinin-piperaquine (DHA-PPQ) is a new co-formulated and well tolerated ACT,
increasingly used in Southeast Asia where it has proved to be highly effective against
Plasmodium falciparum malaria. We tested the efficacy, safety and tolerability of DHA-PPQ in
patients with uncomplicated P. falciparum malaria. A RCT to evaluate DHA-PPQ was carried out,
between 2003 and 2005. Patients with uncomplicated P. falciparum malaria were randomly
allocated to receive either DHA-PPQ or MAS3 with a 63-day follow-up period. Five hundred
twenty two patients were included in the analysis, 262 were allocated to receive DHA-PPQ, and
260 to receive MAS3. The two groups were comparable at baseline in demographic and clinical
characteristics. The mean time for parasite clearance into the DHA-PPQ group was 32. 0 hours
and 35. 5 hours in the MAS3 group. Twenty-four hours after the first dose, the proportions of
patients whose cleared parasitaemia were 67. 2% in the DHA-PPQ group, and 58. 1% in the MAS3
group (RR 1. 25, [95% CI 1. 03âˆ’1. 52], p = 0. 017). All patients were able to clear parasites
within 72 hours after the first dose. The mean time for fever clearance was 28. 0 and 29. 5
hours in DHA-PPQ and MAS3 group respectively. (P= 0. 69). Twenty-four hours after the first
dose, 85. 5% and 83. 1% of patients cleared fever in the DHA-PPQ and MAS3 group respectively
(p>0. 05). The Adequate Clinical and Parasitological Response (ACPR), PCR adjusted, were 97. 7%
and 99,2% for the DHA-PPQ and MAS3 group respectively, (RR 0. 99, 95% CI [0. 86âˆ’1. 13], P =
0. 88). No Early Treatments Failures were reported in any group. In the DHA-PPQ group,
according to the PCR adjusted results, 6 subjects had Late treatment Failures. In the MAS3
group, two Late Treatment Failures was reported. The frequency of adverse events was
significantly lower in patients treated with DHA-PPQ than in those treated with MAS3.
DHA-PPQ proved to be a highly effective antimalarial drug for the treatment of P. falciparum
malaria and suitable for use in the Peruvian Amazon region. It also has the advantage of
being better tolerated. In terms of cost, DHA-PPQ is cheaper and more affordable than MAS3
and should be considered for the National Antimalarial Drug Policy in PerÃº.
Intraductal Meibomian Gland Probing Trial [Recruiting]
In this research study, the investigators are looking at the effects of Meibomian Gland
Probing (MGP) versus a sham (fake) procedure in patients with refractory MGD who have
already tried traditional management with no success in resolving their clinical signs (as
seen by their ophthalmologist) or their symptoms.
The investigators are also evaluating the effects of using two (2) post-procedural
medication treatments: Blephamide or GenTeal PM Night-Time to determine if treatment after
the MGP procedure has an effect on its outcome.
Patients Response to Early Switch To Oral:Osteomyelitis Study [Not yet recruiting]
Based on the current literature, investigators hypothesize that patients with osteomyelitis
who are treated with the standard approach of intravenous antibiotics for the full duration
of therapy will have the same clinical outcomes as patients treated with the experimental
approach of intravenous antibiotics with early switch to oral antibiotics.
The primary objective of this study is to compare patients with osteomyelitis treated with
the standard approach of intravenous antibiotics for the full duration of therapy versus
patients treated with intravenous antibiotics with an early switch to oral antibiotics in
relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy.
Secondary objectives of the study include the evaluation of adverse events related to the
use of antibiotics as well as the cost of care evaluated from the hospital perspective.
Page last updated: 2008-07-28